UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  June 10, 2014

 

PTC THERAPEUTICS, INC.

(Exact Name of Company as Specified in Charter)

 

Delaware

 

001-35969

 

04-3416587

(State or Other Jurisdiction
of Incorporation)

 

(Commission
File Number)

 

(IRS Employer
Identification No.)

 

100 Corporate Court

 

 

South Plainfield, NJ

 

07080

(Address of Principal Executive Offices)

 

(Zip Code)

 

Company’s telephone number, including area code:  (908) 222-7000

 

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

 

o         Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o         Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o         Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o         Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


 

Item 5.07                                           Submission of Matters to a Vote of Security Holders

 

PTC Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders on June 10, 2014. The final results for the votes regarding each proposal are set forth below.

 

The stockholders of the Company elected three Class I directors to hold office until the 2017 annual meeting of stockholders and until their successors are duly elected and qualified as follows:

 

Director

 

For

 

Withheld

 

Broker Non-Votes

 

Stuart W. Peltz, Ph.D.

 

22,625,591

 

11,968

 

1,658,016

 

Jerome B. Zeldis, M.D., Ph.D.

 

22,550,786

 

86,773

 

1,658,016

 

Ronald C. Renaud, Jr.

 

22,625,286

 

12,273

 

1,658,016

 

 

The ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2014 was approved by the Company’s stockholders with 24,293,145 votes “For,” 2,323 votes “Against” and 107 votes “Abstained.”

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

PTC THERAPEUTICS, INC.

 

 

 

 

Date: June 11, 2014

 

By:

/s/ Shane Kovacs

 

 

 

Shane Kovacs

 

 

 

Chief Financial Officer

 

3